Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cyclophosphamide and rabbit antithymocyte globulin followed by autologous hematopoietic stem cell transplantation for severe multiple sclerosis
2006-002562-19Phase 2Active
- Sponsor
- University of Genoa
- Start
- Jan 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and antithymocyte globulin rabbit in multiple sclerosis (MS), sponsored by University of Genoa. Primary endpoints: Safety of ASCT with cyclophosphamide and ATG conditioning and Effect on gadolinium-enhanced MRI lesions. Started Jan 2007; status: active.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-002562-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002562-19.